📋 Tender Overview
Teva Pharmaceuticals a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that eight abstracts examining real-world data to better understand the use of AJOVY fremanezumab-vfrm injection in patients with migraine will be presented at the 2022 American Headache Society AHS Annual Meeting held June 9-12 2022 in Denver Colorado.The data presented at this years AHS meeting will focus on real-world use of AJOVY across different patient populations. Featured data will include a late-breaking poster presentation on real-world evidence in patients using concomitant gepants for acute migraine treatment as well as results of a subgroup analysis from the Phase 3b FOCUS study examining the use of AJOVY in patients with difficult-to-treat migraine and comorbid obesity. In addition a real-world effectiveness study of AJOVY in patients with refractory migraine who switched from erenumab will be highlighted at the meeting.June is Migraine and Headache Awareness month a time that reminds us that while there have been many advances recently in the migraine treatment landscape there is still work to be done said Denisa Hurtukova MD VP Head of North America Medical Affairs. At this years AHS meeting we are looking forward to presenting new real-world research that underscores the impact AJOVY can have on people with specific migraine treatment needs across different clinical circumstances.This years annual AHS meeting is being offered both in person and virtually. Data presentations can be accessed by registering for the meeting.The full set of Teva-sponsored AJOVY data to be presented includesLate-breakingReal-World Effectiveness and Tolerability of Fremanezumab for the Preventive Treatment of Migraine in Patients Using Concomitant Gepants for Acute Treatment in a US Neurology Practice TGT-72562De novoReal-World Effectiveness of Fremanezumab in Patients with Refractory Migraine from a US Tertiary Headache Center Who Switched from Erenumab TGT-72532Real-World Reductions in Migraine-Related Healthcare Resource Utilization and Medication Use with Fremanezumab Treatment in US Migraine Patients Using Concomitant Acute Gepants TGT-72533Real-World Impact of Fremanezumab on Migraine-Related Health Care Utilization and Costs in Patients with Common Comorbidities Acute Medication Overuse or Difficult-to-Treat Migraine TGT-72549Reductions in Acute Medication Use Migraine-Related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab Results of a Long-Term US Claims Database Analysis TGT-72550Efficacy and Safety of Fremanezumab in Patients with Obesity and Difficult-to-Treat Migraine Subgroup Analysis of the Randomized Double-Blind Phase 3B FOCUS Study TGT-72561Primary Headache Disorders and Acute Abortive Medications Associated with Patients Diagnosed with Medication Overuse Headache Analysis of German EMR Data TGT-73146EncoreResponse to Fremanezumab for Preventive Treatment in Migraine in Routine Clinical Practice First Data from the FINESSE study TGT-72567About AJOVY fremanezumanb-vfrm InjectionAJOVY is available as a 225 mg1.5 mL single dose injection in a prefilled syringe or autoinjector with two dosing options 225 mg administered monthly as one subcutaneous injection or 675 mg every three months quarterly which is administered as three subcutaneous injections. AJOVY can be administered in office by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment. AJOVY is now approved in 45 countries worldwide.
